Reconstruction of the swine pulmonary artery using a graft engineered with syngeneic cardiac pericytes by Alvino, Valeria V et al.
                          Alvino, V. V., Thomas, A. C., Ghorbel, M., Rapetto, F., Narayan, S.,
Kilcooley, M., Iacobazzi, D., Carrabba, M., Fagnano, M., Cathery, W.
R., Avolio, E., Caputo, M., & Madeddu, P. R. (2021). Reconstruction
of the swine pulmonary artery using a graft engineered with syngeneic
cardiac pericytes. Frontiers in Bioengineering and Biotechnology, 9,
[715717]. https://doi.org/10.3389/fbioe.2021.715717
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.3389/fbioe.2021.715717
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via Frontiers Media at
https://www.frontiersin.org/articles/10.3389/fbioe.2021.715717/abstract . Please refer to any applicable terms of
use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the
published version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/
Reconstruction of the Swine
Pulmonary Artery Using a Graft
Engineered With Syngeneic Cardiac
Pericytes
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Srinivas A. Narayan, Michael Kilcooley, Dominga Iacobazzi, Michele Carrabba,
Marco Fagnano, William Cathery, Elisa Avolio, Massimo Caputo* and Paolo Madeddu*
Bristol Medical School, Faculty of Health Sciences, University of Bristol, Bristol, United Kingdom
The neonatal heart represents an attractive source of regenerative cells. Here, we report
the results of a randomized, controlled, investigator-blinded preclinical study, which
assessed the safety and effectiveness of a matrix graft cellularized with cardiac
pericytes (CPs) in a piglet model of pulmonary artery (PA) reconstruction. Within each
of five trios formed by 4-week-old female littermate piglets, one element (the donor) was
sacrificed to provide a source of CPs, while the other two elements (the graft recipients)
were allowed to reach the age of 10 weeks. During this time interval, culture-expanded
donor CPs were seeded onto swine small intestinal submucosa (SIS) grafts, which were
then shaped into conduits and conditioned in a flow bioreactor. Control unseeded SIS
conduits were subjected to the same procedure. Then, recipient piglets were randomized
to surgical reconstruction of the left PA (LPA) with unseeded or CP-seeded SIS conduits.
Doppler echocardiography and cardiac magnetic resonance imaging (CMRI) were
performed at baseline and 4-months post-implantation. Vascular explants were
examined using histology and immunohistochemistry. All animals completed the
scheduled follow-up. No group difference was observed in baseline imaging data. The
final Doppler assessment showed that the LPA’s blood flow velocity was similar in the
treatment groups. CMRI revealed amismatch in the average growth of the grafted LPA and
contralateral branch in both treatment groups. Histology of explanted arteries
demonstrated that the CP-seeded grafts had a thicker luminal cell layer, more
intraparietal arterioles, and a higher expression of endothelial nitric oxide synthase
(eNOS) compared with unseeded grafts. Moreover, the LPA stump adjacent to the
seeded graft contained more elastin and less collagen than the unseeded control.
Syngeneic CP engineering did not accomplish the primary goal of supporting the
graft’s growth but was able to improve secondary outcomes, such as the luminal
cellularization and intraparietal vascularization of the graft, and elastic remodeling of the
recipient artery. The beneficial properties of neonatal CPs may be considered in future
bioengineering applications aiming to reproduce the cellular composition of native arteries.
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INTRODUCTION
Congenital defects of the pulmonary artery (PA) can occur as an
isolated lesion or as an element of complex heart anomalies, as
in the case of Tetralogy of Fallot. For patients with isolated
valvular stenosis, balloon valvuloplasty is the treatment of
choice; whereas patients with more complex defects require a
palliative shunt intervention followed by, often multiple,
attempts of definitive correction (Lenoir et al., 2017).
Prosthetic or biological materials used for PA reconstruction
are not ideal substitutes due to their thrombogenicity, limited
durability, and inadequate growth and regeneration potential
(Manavitehrani et al., 2019). Tissue engineering aims to create
advanced therapy medicinal products (ATMPs) endowed with
normal tissue function including capacity for growth and self-
repair (Cheema et al., 2012; Durko et al., 2020; Majid et al.,
2020). Cellularized vascular grafts can potentially overcome the
shortcomings of currently used materials, and, if successfully
passing all the development phases required for a marketing
authorization, they might provide a better solution for the
pediatric population. Several cell populations have been
tested in animal models, including mesenchymal stromal
cells, endothelial cells or induced pluripotent stem cells, yet
the quest for the ideal cell type(s) is still open, as reviewed in
(Avolio et al., 2015a; Jover et al., 2021).
The ideal cell product should confer the graft with rapid (re)
endothelialization, which is critical for inhibiting thrombosis, and
with remodeling capacity to match the characteristics of a normal
artery and the rapid growth of the baby’s heart. Moreover, cell
provision and manufacturing protocols should be tailored to the
time of diagnosis and priorities in patient management. Cells
from fetal tissues, such as the placenta, amnion, and umbilical
cord, are best suited for cases diagnosed prenatally (Bongso et al.,
2008; Pappa and Anagnou, 2009). In line with this, we reported
the feasibility of using prosthetic conduits engineered with
umbilical cord-derived mesenchymal stromal cells for the
reconstruction of the PA in piglets (Ghorbel et al., 2019; Swim
et al., 2019). In cases requiring a two-stage correction, cells from
an accessible post-natal tissue, like the thymus (Iacobazzi et al.,
2018; Albertario et al., 2019), or leftover material of palliative
cardiac shunt surgery, could offer a scope to engineer available
prostheses (Avolio et al., 2015b). Accordingly, we have proposed
cardiac pericytes (CPs) as a cell source to engineer prosthetic
grafts for the correction of right ventricle (RV) outflow defects
(Alvino et al., 2020). In this pilot study, human or swine neonatal
CPs were seeded onto decellularized swine small intestinal
submucosa (SIS, CorMatrix) and cultured under static
conditions for 5 days, followed by maturation of conduit-
shaped SIS in a flow bioreactor. Immunohistological analyses
showed the viability and integration of CPs in the outer layer of
the conduit, and mechanical tests documented an improved
elasticity of the CP-seeded SIS in comparison with the
unseeded material (Alvino et al., 2020). Control and CP-
engineered conduits were then used to replace the left PA of
piglets. After 4 months, anatomical and functional integration of
the grafts was confirmed using Doppler echography, cardiac
magnetic resonance imaging, and histology (Alvino et al., 2020).
To make a step forward in the translational pathway, we have
now designed a randomized, controlled preclinical study aimed at
testing the effectiveness of implanting CP-engineered conduits in
piglets using the same surgical procedure employed to
reconstruct the PA in humans. The endpoints were 1) the
growth of the grafted PA, as assessed using cardiac magnetic
resonance imaging (MRI) at baseline and 4-months follow-up,
and 2) histological evidence of graft remodeling.
METHODS
Data Communication Policy
The article adheres to the guidelines for implementation of the
transparency and openness promotion of science. Following this
policy, the authors will make the data, methods used in the
analysis, and materials used to conduct the research available to
any researcher for purposes of reproducing the results or
replicating the procedure.
Ethics
Institutional review board approval for the study was obtained
according to the guidelines noted in the Journal Instructions to
Authors. Animal experiments were performed in accord with
institutional guidelines and followed the principles stated in the
Guide for Care and Use of Laboratory Animals published by the
National Institutes of Health in 1996 and the Animals (Scientific
Procedures) Act published in 1986. The protocol was covered by
the United Kingdom Home Office ethical approval PPL 30/3019
and PF6E6335D. The report of experimental data followed the
Animal Research: Reporting of In Vivo Experiments (ARRIVE)
guidelines (Percie du Sert et al., 2020).
Manufacture and Quality Validation of Graft
Cellularization
For each round of in vivo implantation, two SIS conduits
(CorMatrix® ECM®, CorMatrix Cardiovascular, Sunnyvale,
CA) were prepared as described previously (Alvino et al.,
2020), along with another conduit for quality validation of cell
number and viability. In brief, CPs were isolated from swine
hearts using an adaptation of the good manufacturing practice-
compliant standard operating procedure previously used for
human hearts. Single cell suspensions were sorted with anti-
human immunomagnetic microbeads (Miltenyi Biotech,
United Kingdom). Then, CD31−and CD34+ CPs were seeded
and expanded to reach passage 4-5, in 4 weeks. The antigenic
phenotype of expanded CPs was described previously (Alvino
et al., 2020). These cells typically express the pericyte marker
NG2, as well as the mural/mesenchymal markers platelet-derived
growth factor receptor beta (PDGFRβ), α-SMA, vimentin, ecto-5-
nucleotidase (eNT/CD73), and calponin (CALP), while being
negative for CD146, CD31, and the hematopoietic marker CD45.
Expanded cells were then used to cellularize an SIS sheet (seeding
density of 20 x 103 cells/cm2) while another sheet, cut from the
same batch, was left unseeded. The optimal seeding density was
validated previously, with the maintenance of cell viability being
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FIGURE 1 | General outcome and imaging endpoints of the randomized, controlled preclinical study. (A) Schematic of the study. (B) Body weight of animals
randomized to the two groups. (C)Representative images of Doppler echocardiography. Vascular structures are highlighted in the images: a  aorta, lpa  left pulmonary
artery, mpa main pulmonary artery, rpa  right pulmonary artery. (D)Column graph and individual Doppler data in the two groups at baseline and 4-moths follow-up. (E)
Representative images of the cardiac MRI showing transversal and longitudinal sections of the site of grant implantation delimited by the red lines. (F–I) Column
graph and individual MRI data (diameter and blood flow) in the two groups at baseline and 4-months follow-up regarding the LPA (F,H) and RPA (G,I). (J) Correlation
between diameter and blood flow regarding LPA and RPA. Abbreviations: BF  blood flow, BW  body weight. N  5 biological replicates per experimental group. Data
are expressed as mean ± SEM.
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the decision criteria (Alvino et al., 2020). Both sheets were kept
under static conditions for 5 days and then shaped into a conduit
and conditioned in a flow bioreactor (3DCulturePro™
Bioreactors, TA Instruments, United Kingdom) at 24 ml/min
for 7 days.
Conduit characterization was performed on samples from
parallel conduits taken after bioreactor maturation and before
surgery. The number of cells on the conduit was estimated using a
CCK-8 assay (CCK8 Cell Counting Kit-8, Sigma). In brief, a
standard curve was established using increasing concentrations of
CPs in a 96-well plate (0–50,000 CP per well in duplicate). Two
small pieces of each experimental conduit were placed into
separate wells of the same plate immediately after removal
from the bioreactor and covered with medium. A piece of
bioreactor-matured unseeded conduit served as a negative
control. After 2 h incubation with the CCK8 reagent the
supernatant was removed from the wells containing the
conduit pieces and the standard curve to measure the optical
density (OD) using a Dynex Opsys MRmicroplate reader (Aspect
Scientific, United Kingdom) set to 450 nm wavelength. The CPs
from the standard curve wells were washed in PBS, trypsinized
and counted. For calculation of the cell density, the area of
conduits was measured using calipers and then the number of
cells/cm2 was then calculated.
Cell viability was assessed using a CalceinAM/EthDIII live/
dead assay (Biotium or Thermofisher, United Kingdom). Viable
cells were observed using a Zeiss AxioObserver.Z1 microscope
attached to a Leica DMi8 inverted epifluorescence microscope.
In Vivo Protocol
Type of study: A randomized, controlled, and operator-blinded
pre-clinical study comparing swine implanted with CP-seeded or
unseeded SIS conduits. Figure 1A illustrates a schematic of the
study protocol.
Endpoints: Cardiac MRI indices of the PA dimensions and
flow and histological evidence of graft remodeling.
Randomization: Within each of five trios formed by 4-week-
old Landrace female littermate piglets, one element (the donor)
was sacrificed to provide a source of CPs, while the other two
elements (the graft recipients) were randomized to the two arms
of the study, at 10 weeks of age, using a SAS Random Number
Generator software. A total of 10 piglets (5 per arm) entered the
study. One arm had the left PA (LPA) reconstructed with an
unseeded SIS conduit and the other with a CP-cellularized SIS
conduit (∼9 mm long and ∼6 mm in diameter). Each conduit had
a code to allow the identification of treatment at completion of the
data analysis.
Surgery: The procedure was conducted at the University of
Bristol Translational Biomedical Research Centre (Langford) by a
team composed of M.C. (principal surgeon) assisted by M.T.G.
and F.R. All team participants were blinded to the group
assignment. During surgery, the swine were maintained under
general anesthesia and neuromuscular blockade. Animals
recovered under intense postoperative monitoring for the
initial 24 h. In brief, the pigs were observed continuously until
awake and were then monitored closely at least every 2 h (chest
drained, blood pressure, pulse, respiration, and temperature
measured, and food, water, urine, and feces noted), with fluids
IV continuously. Analgesia was given every 4 h IV and antibiotics
every 6 h. When not observed directly, the animals remained
under observation using close-circuit TV.
Follow-up: Imaging studies were performed at baseline and
4 months after implantation using a cardiac MRI 3-T scanner
(Siemens Healthcare, Erlangen, Germany) and data were
analyzed by an investigator blinded to the randomization
protocol (S.N.). The heart and pulmonary arteries were also
examined using 2-dimensional Doppler echocardiography
(VividQ; GE Healthcare, Cardiff, United Kingdom), and flow
velocity within the graft and nearby vessels measured by an
investigator blinded to the randomization protocol (M.G.). At
sacrifice, the LPA and other tissues were harvested and processed.
Sections were used for histology, immunohistochemistry, and
morphometric analyses, as described in detail previously (Alvino
et al., 2020).
Immunohistochemistry of Explanted Swine
Grafts
Immunohistochemical analyses of LPA stumps and adjacent
grafts were performed separately by circumscribing the two
tissue areas according to the suture point and the difference in
the immunohistochemical coloring of the intima and media
layers of the native LPA.
Tissue embedding and processing: The conduits harvested from
the animals were opened out, cut into small pieces, and fixed in
4% (w/v) paraformaldehyde (PFA). Samples were put in 30% (w/
v) sucrose, embedded in optimal cutting temperature (OCT)
compound to obtain frozen tissues, or processed using the
Excelsior AS automated processor (Thermo Fisher,
United Kingdom) and embedded in paraffin. Negative controls
for immunohistochemistry included tissue sections without
primary antibodies as technical internal control. Positive
control samples that are not indicated in this manuscript were
shown previously (Alvino et al., 2020). Analyses were performed
using the whole section area, on at least two non-consecutive
sections per animal.
General overview of the tissue’s structure: Hematoxylin and
eosin (H&E) and Verhoeff’s elastic stain (EVG) stainings were
performed on frozen sections to assess the tissue’s structure and
to measure the luminal side of the grafts, the distribution of cells,
and the composition of the extracellular matrix (ECM). Frozen 8-
μm-thick sections were cut using the cryostat STAR Nx50
(Thermo Fisher, United Kingdom) set at −20°C and fixed in
ice-cold glacial acetone (Fisher, United Kingdom) for 5 min at
−20°C. Fixed sections were kept air-dried for 15 min and hydrated
in 1xPBS for 10 min at RT. Staining was performed using a
Shandon Varistan 24–4 slide stainer (Thermo Fisher,
United Kingdom), according to the manufacturer’s
instructions. Slides were mounted with DPX, covered with
coverslips, and air-dried. Images were taken using a Zeiss
Observer. Z1 microscope set up on a bright field light path.
Tiling parameters of the Zen Pro software were used to cover the
whole LPA stump and graft using 2.5x and 10x objectives, while
inserts were acquired at higher magnification, as indicated in
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illustrative figures. The area of EVG (purple-black) staining was
expressed as a percentage of the total area using a morphometric
analysis with Image J software (http://rsbweb.nih.gov/ij/).
Assessment of collagen: Five-μm-thick paraffin-embedded
sections were cut using a Shandon Finesse 325 manual
microtome (Thermo Fisher, United Kingdom) and assessed for
fibrosis using the Azan Mallory histochemical technique. Before
using immunohistochemistry, the paraffin-embedded sections
were subjected to the antigen retrieval to unmask the epitopes
within the tissue, using citrate buffer 0.02mol/L, pH  6 for 30min
at +98°C. All the images, inserts, and tiling parameters were taken
using the same microscope indicated above. Collagen deposits in
the form of blue staining within the LPA stump and adjacent graft
were quantified as the percentage of the total area using Image J
software for themorphometric analysis. The ratio of elastic fibers to
collagen was then calculated.
Quantification of intraparietal vascular smooth muscle cells:
Paraffin-embedded sections were used to assess the newly formed
muscular layer underneath the luminal endothelium of the graft. For
the detection of vascular smooth muscle cells (VSMCs), anti-α-SMA-
cy3 conjugated (1:400, Sigma-Aldrich, United Kingdom) was
incubated with tissue sections for 16 h, at +4°C. Nuclei were
stained with (v/v) DAPI solution and then sections were mounted
with Fluoromount G. Fluorescent images were taken using the Zeiss
Observer. Z1 microscope with 10x and 20x objectives set up on the
fluorescent light path as indicated in the figures.
Assessment of the endothelialization and quantification of
microvascular density: Endothelial cells (ECs) covering the
LPA intima and the adjacent graft were recognized using anti-
human CD31 (1:50, R&D systems, United Kingdom) for 16 h at
+4°C. We have previously demonstrated that anti-human CD31
selectively binds this transmembrane receptor expressed on porcine
endothelial cells. In addition, the use of a highly adsorbed secondary
antibody conjugated to CD31 ensures a high level of IHC specificity in
the lumen of endothelial cells (Alvino et al., 2020). Frozen sections
were incubatedwithAlexa Fluor 647-conjugated highly adsorbed anti-
mouse IgG (1:200, for 1 h, at +20°C, Life Technologies,
United Kingdom). Slides were stained with 1:1,000 (v/v) DAPI
solution in 1xPBS and mounted with Fluoromount G for the
imaging. Representative images were taken with 20x objectives
using Zeiss Observer. Z1 fluorescent microscope. In addition,
paraffin-embedded sections were incubated with anti-isolectin GS-
IB4, which detects the sugar residues of the EC glycocalyx (Life
Technologies, United Kingdom, 1:200), followed by Alexa Fluor 488
Streptavidin secondary antibody (Invitrogen, United Kingdom, 1:200,
1 h, RT). For the assessment of intraparietal microvessels, the sections
were stained with anti-human CD31 and anti-isolectin GS-IB4 to
recognize ECs. In arterioles, VSMCs were identified by staining with
anti-α-SMA cy3-conjugated antibody, as for the quantification of
intraparietal VSMCs. Nuclei were stained with (v/v) DAPI solution
and then sections were mounted with Fluoromount G. The density of
capillaries and arterioles (number permm2)was assessed for thewhole
section area comprising the LPA stump, from where the vasculature
originates, and the adjacent graft. The vascular densities of the two
groups were then compared separately within the stump and the graft.
Quantification of NG2+ vessels: For the detection of pericytes,
frozen sections were incubated with an anti-swine NG2 (1:50,
NovusBio, United Kingdom) followed by Alexa Fluor 488-
conjugated anti-rabbit IgG secondary antibody. The same
sections were treated with anti-human CD31 and anti-α-SMA, all
incubated for 16 h at +4°C, to discriminate the localization of mural
cells either in the media, adventitia, or in the basement membrane.
Vessels covered with NG2+ pericytes were expressed as a percentage
of total capillaries and arterioles.
Quantification of eNOS expression: Paraffin-embedded sections
were stained with anti-human endothelial nitric oxide synthase
(eNOS) primary antibody (1:100, Abcam, United Kingdom). The
presence of the molecule in the form of brown precipitates was
revealed using the REAL EnVision Detection System, 3,3′-
Diaminobenzidine (DAB) kit (Dako, United Kingdom), according
to the manufacturer’s instructions. The images were visualized using
the light microscopy of the Olympus BX40 and QCapture Pro 5.0
software. For the quantitative analysis of eNOS, we used ImageJ
software (http://rsbweb.nih.gov/ij/), converted the RGB images to an
8-bit grayscale image, and then used the threshold tool to set the
threshold color (red channel) corresponding to the area of dark
brown eNOS in the vessels and the endothelial layer of the graft and
LPA Stump.We used theMeasure Tool to calculate the area, which is
the size of the selection within the set threshold. To calculate the
percentage of eNOS area, we divided the dark brown precipitate area
by the total area of the picture. Data were expressed as the percentage
of the total area in mm2. Cross-sections of human placental villi were
used as a positive control to detect eNOS in syncytiotrophoblasts.
Statistical Analysis
The data were collected according to the intention-to-treat
concept. (Gupta, 2011; McCoy, 2017). Statistical significance
for differences between the two experimental groups was
determined using Student’s t-test. When assessing the effect of
two variables and their interaction, two-way ANOVA, with post-
hoc Sidak’s test was used. Data are expressed as individual values
and means ± SEM. Probability values (P) < 0.05 were considered
significant.
RESULTS
Quality Validation of Graft Cellularization
After Bioreactor Conditioning
The viability of CPs seeded in the SIS conduit was 96 ± 2% after
5 days of static culture and 91 ± 2% after 7 days of conditioning in
the bioreactor (Supplementary Figure S1). The cell density for
each CP-seeded conduit immediately before engraftment was
84 ± 14 x 103 cell/cm2. Both seeded and unseeded conduits were
formed into custom-sized grafts (9.2 ± 0.3 mm long and 7.2 ±
0.2 mm diameter) immediately before implantation.
General Outcome and Imaging Endpoints of
the Randomized, Controlled, and Blinded
Preclinical Study
All the animals concluded the 4-months follow-up, with a
similar body weight increase in the two arms of the study
(Figure 1B).
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There was no difference in the pre-implantation imaging
data between the two groups, thus excluding any imbalance
in baseline characteristics causing chance bias. Analysis of
data from the final Doppler did not reveal any group
difference in the blood flow velocity regarding the grafted
LPA or untouched contralateral right branch (RPA) (Figures
1C,D). Representative images of the cardiac MRI are shown
in Figure 1E. The LPA anteroposterior diameter remained
unchanged from baseline to the final assessment in both
groups, whereas the untouched RPA grew over the same
period by 1.79-fold in the unseeded (p < 0.01) and by 1.52-
fold in the seeded group (p < 0.05) (Figures 1F,G). Blood
FIGURE 2 |Cellular composition of the graft: (A)H&E staining of unseeded and seeded grafts. Tiled images and inserts show the general architecture and details of
explanted grafts, including the distribution of cells (cell nuclei are dark blue and eosinophilic compounds in the cytoplasm are pink) and the ECM underneath the luminal
cell layer, containing fibroblasts and microvessels. (B) Bar graph showing the thickness of the luminal layer. N  5 biological replicates per experimental group. Data are
represented asmean ± SEM. *p < 0.05. (C) Immunofluorescent and bright-field images display the presence of CD31 (yellow) and IB4 (green) markers in the luminal
endothelium of the grafts. Representative images are acquired using 2.5x, 10x, and 20x objectives.
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flow increased during the follow-up, although more
remarkably in the untouched RPA (p < 0.001) than in the
grafted LPA (p < 0.05), with no difference between seeded or
unseeded groups (Figures 1H,I). The slope of the relationship
between flow and diameter was similar in the LPA and RPA,
although individual points of the LPA were shifted to the lower-
left corner for the RPA (Figure 1J). These data indicate that the
grafted conduit had limited growth potential, which resulted in
a reduction of the corresponding blood flow. Moreover, these
limitations could not be avoided by the presence of CPs in the
conduit.
Immunohistochemistry Endpoints
Although the imaging methods could not demonstrate the
efficacy of the engineered conduit, histological studies revealed
several important differences between the two arms of the study.
We compared the cellular composition, intraparietal
vascularization, and ECM remodeling of seeded and unseeded
grafts and attached LPA.
Cellular composition of the graft: The H&E staining
demonstrated the structural continuity between the graft
and the attached LPA stump, with a demarcation indicated
by the presence of suture points. As shown in Figure 2A, the
FIGURE 3 | Multicolor fluorescent microscopy shows the luminal layer of the graft is composed of endothelial and smooth muscle cells. (A,B) Images
showing the layer of luminal endothelial cells (green) sitting on several sheets of α-SMA + VSMCs (red) at the level of the LPA stump (A) and the grafts (B). Bar
graphs showing the quantification of IB4 (C) and α-SMA staining measured as percentage of positive expression in the internal layer of total section area (D).
α-SMA was also calculated as thickness layer expressed in μm (E). The images were visualized using a fluorescent microscope with 10x objectives and
bigger inserts were added for better visualization of the details. N  5 biological replicates per experimental group. Data are expressed as mean ± SEM.
*p < 0.05, ***p < 0.0005.
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FIGURE 4 |Microvascular composition of the implanted artery. (A,B) Immunofluorescent microscopy image of the vascularization at the level of the LPA stump and
grafts. In panel A, endothelial cells were stained with CD31 (white), vascular smooth muscle cells with a-SMA (red), pericytes with NG2 (green), and nuclei with DAPI
(blue). In panel B, endothelial cells stained with IB4 (green), vascular smooth muscle cells with α-SMA (red), and nuclei with DAPI (blue). The location of the neo-adventitia
is indicated in each image. Vascular smooth muscle cells are visualized in the tunica media of the LPA stump, the graft structure, and within intraparietal arterioles.
(C–F) Bar graphs showing the vascular density and pericyte coverage in the two groups at the level of the LPA stump and grafts (C) Total vascular density, (D) Capillary
density, (E) arteriole density, (F) NG2+ percentage. N  5 biological replicates per experimental group. Data are expressed as mean ± SEM. *p < 0.05, **p < 0.01.
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LPA stump was composed of three distinct layers, the intima,
tunica media, and abluminal adventitia. The graft showed a
luminal layer of longitudinally oriented cells resting on
connective tissue containing microvascular structures and
fibroblastic cells oriented along the ECM fibers. The
morphometric analysis of the luminal layer denoted this
was 2.5-fold thicker in seeded grafts as compared with
unseeded grafts (Figure 2B). We next used
immunofluorescent microscopy to characterize the cell
populations at the level of the lumen and underneath
layer. Staining for CD31, which labels a glycoprotein
expressed on EC, and IB4, which binds to the sugar
residues of the endothelial glycocalyx, demonstrated
stronger signals, as assessed using Image J, in the seeded
grafts compared with the unseeded grafts (Figure 2C).
Moreover, using a combination of fluorescent markers, we
identified VSMCs were located underneath the IB4 positive
endothelium, in continuity with the tunica media of the LPA
stump (Figures 3A–E). Cellularized grafts showed a
significant increase of the IB4 staining in the luminal side
(Figure 3C), whereas the fluorescence intensity and thickness
of the α-SMA positive layer were similar between the two
groups (Figures 3D,E).
Vascular density: The animals implanted with cellularized
grafts had a higher vascular density in the total explant area
compared with the unseeded controls (p < 0.01) (Figures
4A,B). The analysis of distinct areas of the explant revealed that
the increase in vascular density occurred at both the LPA stump
(p < 0.05) and the graft (p  0.05) level (Figure 4C). This could be
attributed to the heightened arteriole density (p < 0.01), whereas
capillary density was similar between seeded and unseeded grafts
(Figures 4D,E). Several vessels within the LPA stump and the graft
were surrounded by NG2+ pericytes. However, the fraction of
NG2+ vessels was similar in the two treatment groups (Figure 4F).
Expression of eNOS: Immunohistochemistry analysis showed
the expression of eNOS by ECs of the luminal layer and
intraparietal microvessels of the LPA stump and graft (Figures
5A,B). Sections of placenta villi were used as a positive control
(Figure 5C). Using two-way ANOVA, we detected a difference in
the global eNOS expression between the two groups, with the
posthoc test confirming a higher expression in seeded grafts
compared with unseeded controls (p < 0.01). Interestingly, the
FIGURE 5 | Expression of eNOS expression in the implanted artery. (A) Light microscopy images displaying the expression of eNOS in the LPA stump and graft in
the form of brown precipitates. An intense staining, continuous staining was detected in endothelial cells of the seeded grafts (both at the luminal side and in intraparietal
microvessels) compared with unseeded grafts. Moreover, weak positive staining could be appreciated in muscular cells underneath the luminal endothelial cells of the
seeded grafts. (B) Bar graph showing the quantification of eNOS staining measured as the percentage of total section area. Images were quantified using a light
microscope with 40x and 100x objectives. N  5 biological replicates per experimental group. Data are expressed as mean ± SEM. **p < 0.01 (C) Cross-sections of
human placental villi (used as a positive control) show the strong expression of eNOS in the syncytiotrophoblasts.
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explanted seeded grafts showed 2.5-fold higher levels of eNOS
compared with corresponding stumps (p < 0.01).
Moreover, two major differences were observed when
zooming into the luminal layer of the grafts (magnification
inserts of Figure 5A). First, the eNOS staining was continuous
in ECs of the seeded graft, at variance with the sporadic
characteristic observed in the unseeded graft. Second,
VSMCs underneath the ECs of seeded grafts were weakly
positive for eNOS, whereas no signal was detected in the
unseeded controls.
FIGURE 6 | ECM remodeling of the implanted artery. (A,B) Tiled images and inserts at higher magnification display the composition of elastic fibers of the LPA and
graft, as assessed using EVG (A) and Azan Mallory (B) stainings. (C–E) Bar graphs showing the results of the quantification of elastin and collagen and their ratio. Images
were visualized using a light microscope with 2.5x, 10x and 20x objectives. N  5 biological replicates per experimental group. per experimental group. Data are
expressed as mean ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001.
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Extracellular matrix remodeling: The LPA stump adjacent to
the seeded graft had a higher content of elastic fibers, as denoted
by the EVG staining, and less collagen, identified by AzanMallory
staining, compared with controls (Figures 6A–E), with these
reciprocal changes resulting in a remarkable increase in the elastic
to collagen content ratio in the LPA stump (Figure 6E). As
expected, the implanted grafts had lesser elastic fiber content than
the corresponding LPAs, with no difference between seeded and
unseeded grafts (Figures 6C,E).
DISCUSSION
The present study is the first to be conducted using a graft
cellularized with syngeneic CPs to reconstruct a branch of the
piglet PA. The model is intended to reproduce the surgical
method used for the correction of congenital anomalies of the
PA. Moreover, we attempted to simulate the clinical scenario
where CPs are isolated from the young heart, expanded, and
implanted within a graft into the PA. In this set of experiments,
we obtained swine donor cells from a recipient’s sibling to avoid
the stress caused by a double intervention.
Feasibility and Safety
Results of the preclinical study confirm that the tissue engineering
protocol is feasible. Moreover, the safety of implantation was
demonstrated by the normal growth of the swine, the absence of
thrombotic events, and the persistent patency of the grafted PAs.
Primary Endpoints of Efficacy
The assessment of the primary endpoints at the 4-months
follow-up did not provide evidence of efficacy. In both arms of
the study, the cardiac MRI showed that the grafted LPA did not
grow to the same extent of the untouched RPA, with the lack of
growth resulting in a defective blood flow through the grafted
artery. No significant difference was observed between the two
treatment groups regarding both the pre-implantation and
final MRI and Doppler data. The similarity in baseline data
excludes the possibility that a chance bias in the initial
randomization has compromised the robustness of the
efficacy analysis.
In our previous study, we anticipated that sample size
should be set at 14 (7 swine per group) (Alvino et al.,
2020). A study of this size would have 80% power to detect
a difference in the Doppler blood flow velocity of 0.3 ml/min
with an SD of 0.2.11 Considering the ethical and financial
challenges associated with the use of swine, we decided to
perform an ad interim recalculation of the group size and cost/
benefit ratio after completion of 10 animals (5 per group)
before engaging in a larger study. The recalculation of the SD
for the Doppler blood flow velocity confirmed a value (0.23)
close to the initial assumption (0.20) but with a null effect size
(0.002). The SD for the MRI assessment of the antero-posterior
diameter of the LPA was 3.01, with an effect size of 1.35
favoring the unseeded graft group compared with the
seeded graft group. Therefore, we concluded there was no
justification to extend the study.
Secondary Endpoint: Improvement of
Endothelialization and Intraparietal
Vascularization
Immunohistochemistry showed that bioengineering of the SIS
graft with swine CPs resulted in a thicker intimal layer and amore
abundant intraparietal vascularization. These results are
compatible with the in vitro data of our previous study
showing swine CPs can recruit ECs and promote endothelial
network formation through the secretion of paracrine factors
(Alvino et al., 2020).
Graft endothelialization is crucial to maintain an anti-
thrombotic surface and preserve the vasodilatory ability of the
reconstructed artery, while vascularization is necessary for the
maintenance of perfusion within the vessel wall (Chang and
Niklason, 2017). Methods to achieve these goals consist of
seeding autologous ECs onto vascular prostheses or decorating
them with angiogenic/chemoattractant factors to recruit ECs
from the anastomotic sites and proangiogenic monocytes from
the circulation (De Visscher et al., 2012; Lee et al., 2013; Smith
et al., 2020). However, these methodologies involved additional
manufacturing steps and showed incomplete endothelialization
especially in the center of the grafts (Smith et al., 2020). Therefore,
the ability of CP-engineered grafts to promote spontaneous
enhancement of the luminal cellularization and intraparietal
vascularization represents a success of the present
preclinical study.
Regarding the underpinning mechanisms, two possibilities
should be considered 1) the seeded cells and/or their
extracellular matrix were entirely responsible for the
recruitment of ECs or 2) the seeded cells have synergized with
the CorMatrix’s native angiogenic properties. In support of the
second possibility, the epicardial implantation of non-cellularized
CorMatrix in a porcine model of coronary ischemia-reperfusion
attenuated the maladaptive remodelling following MI and
promoted healing and functional recovery; in addition, the
matrix reportedly promoted vasculogenesis in the region of
functional recovery (Mewhort et al., 2016). Another study
reporting the use of non-cellularized SIS-ECM was carried out
in a rodent MI model: implantation of an active SIS-ECM patch
on the epicardium had a therapeutic effect on the cardiac
remodelling and functional recovery compared with SIS-ECM
that had been inactivated by exposure to glutaraldehyde or
guanidine hydrochloride (Mewhort et al., 2017). The SIS-ECM
induced a strong vasculogenic response through the formation of
functional blood vessels when in contact with endogenous
fibroblasts, with FGF-2 being the key regulator of the bioactive
effects. This cumulative evidence suggests that acellular SIS-ECM
has intrinsic regenerative capacities.
We attempted to assess the contribution of seeded cells by
verifying their persistence in two grafts that were explanted 12 or
14 days after implantation. In this pilot study, two female swine
were used as recipients and CPs were derived from a brother.
Fluorescent in situ hybridization (FISH) was used to identify cells
expressing the Y chromosome using a protocol described by us
previously (Albertario et al., 2019), with the exception of the
probe, which was purchased from another vendor (Chromosome
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Science Labo, Japan) because the one used in (Albertario et al.,
2019) had been discontinued. Unfortunately, the study was
unsuccessful because the Y chromosome could not be detected
in a positive control (male heart biopsy). This represents a
limitation of our study precluding an interpretation of the
seeded cells’ persistence after implantation in vivo.
Re-endothelialization was associated with an increased
expression of eNOS. The eNOS staining was strong in ECs at
the luminal side of the graft and the endothelium of intraparietal
vessels but could also be appreciated in VSMCs underneath
luminal ECs. The enzyme eNOS is a source of NO, which
diffuses to the VSMCs to induce vasorelaxation (Gao et al.,
2016). Recent studies have suggested that the VSMCs express
eNOS and that VSMC-derived NO can account for vasodilation
even in endothelium-denuded conditions (Han et al., 2013). Since
the pulmonary circulation is operating with distinctively low
arterial pressure, the synergistic effect of EC- and VSMC-
derived eNOS might be underlying the characteristic low PA
resistances (Kim et al., 2019). Reduced expression of eNOS has
been associated with alterations in the structure and endothelial
function of the pulmonary vasculature in smokers and children
with congenital heart defects (Barberà et al., 2001; Ferreiro et al.,
2001). To the best of our knowledge, this is the first report
indicating that bioengineering with CPs can induce long-term
upregulation of eNOS expression in the vascular graft. Further
studies are necessary to determine the mechanism underpinning
eNOS induction and the clinical implication of this phenomenon.
Secondary Endpoint: Elastic Remodelling
Another significant result of graft bioengineering consisted of the
elastic remodeling of the LPA stump. Pulmonary vascular
stiffness refers to an elastic PA’s innate resistance to
deformation under a pressure load and it mainly depends on
the vessel’s inherent material properties. Elevations in stiffness
due to the reduction of the elastic content have been associated
with increased adult mortality and poorer pediatric outcomes
(Mahapatra et al., 2006; Hunter et al., 2008). This association is
believed to be due to several factors, including flow inefficiency,
increased right ventricular afterload independent of pulmonary
vascular resistance, and exacerbation of vascular pathologies
(Hunter et al., 1985).
Results of mechanical tests from our previous study suggested
that CorMatrix conduits acquired a more elastic behavior when
seeded with sCPs, as denoted by a significant decrease in Young’s
modulus, but also an increased strain at rupture (Alvino et al.,
2020). However, these data could not predict the primary
outcomes of the present study, thus suggesting that
mechanical tests require further refinement, including the
comparison of pre- and post-implantation features. This
double assessment was not done in the present study and
represents therefore a limitation.
Critical Comparison of Results With Other
Tissue Engineering Strategies
The failure in achieving the primary endpoint despite positive
secondary outcomes represents an intriguing aspect of the study.
While endothelialization and intraparietal angiogenesis are
important regenerative features, other mechanisms are
necessary for the eutrophic remodelling of the implanted graft.
In recent years, several bioengineering approaches have been
proposed to reach this goal.
We have previously shown that fetal tissues can be a
valuable source of stromal cells for tissue engineering
(Avolio et al., 2015a). The advantage of CPs over umbilical
cord blood-derived stromal cells consists of their superior
purity and defined antigenic phenotype. Moreover, the
differentiation of stromal cells into VSMCs involves an
additional step in manufacturing, which results in increased
complexity and delayed availability, both detrimental for cases
requiring rapid correction. On the other hand, VSMCs derived
from the differentiation of mesenchymal stromal cells
conferred conduits with the growing capacity that was
precluded to CPs (Ghorbel et al., 2019; Iacobazzi et al.,
2021). Considering that human CPs can be also induced to
contractile VSMCs during culture expansion (Ghorbel et al.,
2019), it would be interesting to determine if seeding SIS grafts
with CP-derived VSMCs may improve the graft capacity to
remodel and grow after implantation in vivo.
Functional VSMCs could be efficiently generated on a large
scale from induced pluripotent stem cells (iPSCs). Following
implantation into a rat aortic model, hiPSC-engineered
vascular grafts showed excellent patency without luminal
dilation and effectively maintained mechanical and contractile
function (Luo et al., 2020). Apart from mural cells, grafts
cellularized with autologous ECs (Ma et al., 2017) and
endothelial progenitor cells (Yuan et al., 2020) were used in
preclinical models. This approach is intended to reduce the risk of
early thrombosis and confer the graft with immediate
remodelling capacity (Carrabba and Madeddu, 2018).
Alternative methods using cells as a source of biocompatible
matrix and novel bioprinting devices have been developed in
recent years. For instance, Syedain et al. (2016) showed that off-
the-shelf tubes of fibroblast-derived collagenous matrix can
regenerate and grow as a PA replacement in synchrony with
body growth in lambs. Recently, they implemented the product
to generate a valved conduit consisting of three tubes sewn
together (Syedain et al., 2021). The tri-tube valves demonstrated
resistance to calcification and improved hemodynamic function
compared to clinically used pediatric bioprosthetic valves tested
in the same model (Syedain et al., 2021). Similarly, acellular
grafts made of synthetic material exploit the patient’s body as a
living bioreactor for cellularization in vivo. However, the
endogenous cells’ colonization process is slow, making these
synthetic grafts prone to thrombosis and deformation
(Pashneh-Tala et al., 2016).
Grafts made of decellularized natural blood vessels are
superior regarding biocompatibility. However, the process of
decellularization can damage the extracellular matrix. To
circumvent this limitation, synthetic material has been used to
create a reinforced hybrid vascular graft that was used in a rat
aorta interposition model (Gong et al., 2016; Ran et al., 2019).
New automated technology based on dip-spinning
methodologies were proposed to manufacture constructs with
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native mechanical properties and cell-derived biological activities,
critical for clinical graft applications (Akentjew et al., 2019).
CONCLUSION
Bioengineering of SIS grafts with syngeneic CPs resulted in some
improvements regarding endothelialization but failed in the goal of
conferring the graft with growth capacity. Cell-engineered grafts
hold promises, but none has reached full clinical application. The
main reason being they failed to fully reproduce the structure/
function of native arteries. Accordingly, we are already working
on a second-generation graft, made of a three-layered structure
decorated with specialized vascular cells, including EC, VSMCs, and
adventitial pericytes, aiming to mimic the characteristics of the PA.
IMPLICATIONS OF THE STUDY
1) What is new?
• We have provided evidence for the feasibility of using a
pericyte-cellularized SIS conduit for the reconstruction of
the pulmonary artery in piglets.
• Pericyte engineering improves the in vivo luminal
cellularization and intraparietal vascularization of SIS grafts,
potentially through long-term induction of endothelial nitric
oxide synthase. In addition, the engineered product confers
the recipient artery with elastic features. However, the study
showed no benefit the vessel growth.
2) What are the clinical implications?
• Cardiac pericytes available from leftover tissue of palliative
surgery could be used to engineer clinical-grade matrix
conduits ready for implantation at the occasion of definitive
correction of the pulmonary artery defect. This solution can
accelerate the colonization of the implanted graft by the
recipient’s cells to acquire characteristics of the native
pulmonary artery.
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